GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OWC Pharmaceutical Research Corp (OTCPK:OWCP) » Definitions » Sloan Ratio %

OWC Pharmaceutical Research (OWC Pharmaceutical Research) Sloan Ratio % : 0.00% (As of Sep. 2019)


View and export this data going back to 2008. Start your Free Trial

What is OWC Pharmaceutical Research Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

OWC Pharmaceutical Research's Sloan Ratio for the quarter that ended in Sep. 2019 was 0.00%.

As of Sep. 2019, OWC Pharmaceutical Research has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


OWC Pharmaceutical Research Sloan Ratio % Historical Data

The historical data trend for OWC Pharmaceutical Research's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OWC Pharmaceutical Research Sloan Ratio % Chart

OWC Pharmaceutical Research Annual Data
Trend Dec08 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only -291.33 -101.40 -353.32 -316.97 -217.59

OWC Pharmaceutical Research Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -99.19 -217.59 - - -

Competitive Comparison of OWC Pharmaceutical Research's Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, OWC Pharmaceutical Research's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OWC Pharmaceutical Research's Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, OWC Pharmaceutical Research's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where OWC Pharmaceutical Research's Sloan Ratio % falls into.



OWC Pharmaceutical Research Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

OWC Pharmaceutical Research's Sloan Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2018 )-Cash Flow from Operations (A: Dec. 2018 )
-Cash Flow from Investing (A: Dec. 2018 ))/Total Assets (A: Dec. 2018 )
=(-10.258--2.499
--0.028)/3.553
=-217.59%

OWC Pharmaceutical Research's Sloan Ratio for the quarter that ended in Sep. 2019 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Sep. 2019 )
=(1.34--2.743
--0.007)/1.773
=230.68%

OWC Pharmaceutical Research's Net Income for the trailing twelve months (TTM) ended in Sep. 2019 was -5.08 (Dec. 2018 ) + -1 (Mar. 2019 ) + 7.707 (Jun. 2019 ) + -0.287 (Sep. 2019 ) = $1.34 Mil.
OWC Pharmaceutical Research's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2019 was -0.751 (Dec. 2018 ) + -0.665 (Mar. 2019 ) + -0.955 (Jun. 2019 ) + -0.372 (Sep. 2019 ) = $-2.74 Mil.
OWC Pharmaceutical Research's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2019 was -0.005 (Dec. 2018 ) + 0 (Mar. 2019 ) + -0.002 (Jun. 2019 ) + 0 (Sep. 2019 ) = $-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OWC Pharmaceutical Research  (OTCPK:OWCP) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Sep. 2019, OWC Pharmaceutical Research has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


OWC Pharmaceutical Research Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of OWC Pharmaceutical Research's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


OWC Pharmaceutical Research (OWC Pharmaceutical Research) Business Description

Traded in Other Exchanges
N/A
Address
2 Ben Gurion Street, Ramat Gan, ISR, 5257334
OWC Pharmaceutical Research Corp is a medical cannabis research and development company. The firm through its subsidiary researches and develops cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD), migraine, sexual function and skin disorders. It also provides consulting services to governmental and private entities to assist them with developing and implementing tailor-made medical cannabis program.
Executives
Asher Zwebner director, officer: CHIEF FINANCIAL OFFICER CDOOR CORPORATION, 20 A REHOV SHAREI TORAH BAYIT VEGAN, JERUSALEM L3 96387

OWC Pharmaceutical Research (OWC Pharmaceutical Research) Headlines